American College of Cardiology

APRIL 6, 2024

The goal of the EMPACT-MI trial was to determine whether adding the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin to the treatment of acute myocardial infarction (AMI) affects future mortality or heart failure (HF) in at-risk patients.

Myocardial Infarction 65

Myocardial Infarction Heart Failure Hospital Article 65

Science Daily - Heart Disease

JUNE 10, 2024

New research discovers a potential path to prevent permanent scarring and heart failure following a myocardial infarction.

Heart attacks 114

Heart attacks Heart Attack Myocardial Infarction Heart Failure 114

The New England Journal of Medicine

APRIL 5, 2024

A number of therapies that have been shown to be effective in patients with chronic heart failure, including beta-blockers, mineralocorticoid receptor antagonists, and renin–angiotensin system inhibitors, have also been shown to be beneficial in patients with evidence of left ventricular systolic dysfunction, pulmonary congestion, or both after an (..)

Heart Failure 73

Heart Failure Myocardial Infarction Pulmonary 73

Cardiovascular Diabetology

APRIL 26, 2024

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have been suggested to exert cardioprotective effects in patients with heart failure, possibly by improving the metabolism of ketone bodies in the myocardium.

Myocardial Infarction 105

Myocardial Infarction Heart Failure Research 105

Science Daily - Heart Disease

AUGUST 30, 2024

The appropriate duration of beta-blocker treatment after a heart attack (a myocardial infarction [MI]) is unknown in patients who do not need to take beta-blockers for another reason.

Heart Attack 130

Heart Attack Heart attacks Quality of Life Myocardial Infarction 130

Cardiovascular Diabetology

JANUARY 21, 2025

The impact of sodiumglucose cotransporter-2 (SGLT2) inhibitors on mortality following myocardial infarction (MI) remains uncertain. Additionally, the role of type 2 diabetes mellitus (T2DM) and heart failure.

Myocardial Infarction 64

Myocardial Infarction Heart Failure Diabetes Research 64

Frontiers in Cardiovascular Medicine

FEBRUARY 24, 2025

This case report describes a unique instance of a patient developing AEF following AF ablation, accompanied by ischemic stroke and myocardial infarction. Upon admission, physical examination and laboratory tests revealed vital signs within abnormal ranges and indicators suggesting inflammation and potential myocardial injury.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Cardiogenic Shock Myocardial Infarction 52

Science Daily - Heart Disease

DECEMBER 16, 2024

atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. Significant complications associated with this condition include ischemic stroke, heart failure, myocardial infarction, chronic kidney disease, dementia and mortality.

Atrial Fibrillation 111

Atrial Fibrillation Myocardial Infarction Kidney Disease Dementia 111

Cardiovascular Diabetology

JANUARY 8, 2024

Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Myocardial Infarction Kidney Disease Diabetes 105

CardiacWire

APRIL 21, 2024

A BMJ study out of Denmark provided alarming new insights into atrial fibrillation’s impact on patients’ future cardiovascular health, while highlighting the need to improve post-AFib heart failure and stroke prevention. Heart failure was the most frequent post-AFib complication with a 41.2% in 2000-2010 to 30.9%

AFIB 105

AFIB Heart Failure Myocardial Infarction Stroke 105

Circulation: Heart Failure

MARCH 26, 2025

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Myocardial Infarction Circulation 40

Open Heart

SEPTEMBER 13, 2024

Background In acute heart failure (HF), reduced cardiac output, vasoconstriction and congestion may damage the intestinal mucosa and disrupt its barrier function. We aimed to investigate gut leakage markers and their associations with inflammation, infarct size and cardiac function.

Cardiac Function 52

Cardiac Function Myocardial Infarction Heart Failure STEMI 52

JAMA Cardiology

APRIL 6, 2024

This secondary analysis of a randomized clinical trial examines the antibody response to high-dose trivalent compared with standard-dose quadrivalent inactivated influenza vaccine in patients with a recent acute myocardial infarction or heart failure hospitalization.

Cardiovascular Disease 95

Cardiovascular Disease Myocardial Infarction Heart Failure Hospital 95

Cardiovascular Diabetology

AUGUST 6, 2024

Data on major cardiovascular events (MACE; mortality, myocardial infarction, stroke, heart failure) through December 2021 were obtained from national registries. Results Among all patients (n = 38,671), 31% had stable CAD, and 69% suffered an acute myocardial infarction.

Coronary Artery Disease 98

Coronary Artery Disease Diabetes Myocardial Infarction Heart Failure 98

Frontiers in Cardiovascular Medicine

APRIL 1, 2025

More than half of the patients presented with heart failure (n=2,234, 55.4%), followed by acute myocardial infarction (n=1,368, 34.0%), coronary artery disease (n=674, 16.7%), and acute coronary syndrome (n=164, 4.1%). Poor ventricular function (26.16.8

Biomarkers 52

Biomarkers Coronary Artery Disease Article Myocardial Infarction 52

HCPLive

FEBRUARY 10, 2025

Cardiovascular hospitalization rates were higher in the US than in Denmark, driven by a significant increase in heart failure and myocardial infarction hospitalizations.

Hospital 78

Hospital Myocardial Infarction Heart Failure 78

All About Cardiovascular System and Disorders

FEBRUARY 27, 2024

Autonomic dysfunction caused by spinal cord injury is associated with abnormalities in blood pressure, heart rate variability, arrhythmias and blunted cardiovascular response to exercise which can limit the capacity to perform physical activity [1]. Survivors with severe disability had the highest risk. Am J Phys Med Rehabil. PMID: 17251696.

Myocardial Infarction 40

Myocardial Infarction Atrial Fibrillation Heart Failure Blood Pressure 40

Open Heart

MARCH 13, 2025

Mediation analyses were performed to assess the proportion mediated by MDD. Results Genetically predicted insomnia, short sleep, daytime napping and daytime sleepiness increased the risk of CVDs, with the OR ranging from 1.24 (95% CI 1.06 to 1.45) for insomnia on stroke to 1.55 (95% CI 1.28 to 1.89) for insomnia on MI.

Cardiovascular Disease 52

Cardiovascular Disease Coronary Artery Disease Myocardial Infarction Atrial Fibrillation 52

Journal of the American Heart Association

APRIL 3, 2025

Journal of the American Heart Association, Ahead of Print. BackgroundMyocardial fibrosis is a pathological hallmark of heart failure post infarction, emphasizing the need for innovative treatment strategies. Mesenchymal stem cellderived EVs, loaded with PAP, were encapsulated in the SA hydrogel (EVsPAP@SA).

Myocardial Infarction 40

Myocardial Infarction Innovation Heart Failure Research 40

Frontiers in Cardiovascular Medicine

DECEMBER 9, 2024

Therefore, this meta-analysis aimed to estimate association between TMAO levels and the prognosis of patients with myocardial infarction (MI).MethodsWe Outcomes included MACE, all-cause mortality, recurrent MI, rehospitalization caused by heart failure, stroke, revascularization, SYNTAX score, and multivessel disease.

Myocardial Infarction 52

Myocardial Infarction Biomarkers Heart Failure Stroke 52

Journal of Cardiovascular Pharmacology

OCTOBER 24, 2024

Myocardial remodeling is characterized by gradual heart enlargement, cardiac dysfunction, and extraordinary molecular changes. Cardiac remodeling after myocardial infarction is almost inevitable, which is the leading cause of heart failure.

Myocardial Infarction 40

Myocardial Infarction Heart Failure Ischemia Heart Disease 40

Frontiers in Cardiovascular Medicine

JANUARY 19, 2025

IntroductionHypoxic liver injury (HLI) and Killip classification are poor prognostic factors in patients with ST-segment elevation myocardial infarction (STEMI). Left ventricular ejection fraction (LVEF) was below 45% in symptomatic, overt heart failure patients (Killip class II, III, and IV).

Myocardial Infarction 52

Myocardial Infarction STEMI Biomarkers Hospital 52

Circulation

NOVEMBER 11, 2024

These challenges highlight the need for new therapies that are both safe and effective in targeting the structural remodeling pivotal to disease progression post-myocardial infarction (MI). Current treatments are limited by side effects, poor patient compliance, and the necessity for gradual drug titration.

Myocardial Infarction 40

Myocardial Infarction Heart Failure Cardiac Function Biomarkers 40

Journal of the American Heart Association

MARCH 27, 2025

BackgroundRecent evidence highlights an increasing incidence of myocardial infarction in young women. years]) admitted to the China Chest Pain Center Database between 2016 and 2021.

Myocardial Infarction 40

Myocardial Infarction Peripheral Arterial Disease Outcomes Chest Pain 40

Frontiers in Cardiovascular Medicine

MARCH 10, 2024

Background Hyperglycemia, characterized by elevated blood glucose levels, is frequently observed in patients with acute coronary syndrome, including ST-elevation myocardial infarction (STEMI). 2.17), heart failure (pooled RR 1.56, 95% CI: 1.37–1.77), 2.18)) with a pooled RR of 1.58 (95% CI 1.26–1.97).

Myocardial Infarction 59

Myocardial Infarction Cardiogenic Shock Article STEMI 59

Journal of Cardiothoracic Surgery

JANUARY 16, 2025

Gout is a metabolic disease caused by decreased blood uric acid excretion and purine metabolism disorders. Long-term and persistent metabolic dysfunction gradually affects other organ functions and is the main.

Myocardial Infarction 52

Myocardial Infarction Heart Failure Research 52

Circulation: Cardiovascular Imaging

APRIL 3, 2025

BACKGROUND:Microvascular obstruction (MVO) is associated with heart failure (HF) following ST-segmentelevation myocardial infarction. Circulation: Cardiovascular Imaging, Ahead of Print.

Heart Failure 40

Heart Failure Myocardial Infarction STEMI Risk Factors 40

Frontiers in Cardiovascular Medicine

JANUARY 3, 2024

Nitrate therapy has potential benefit in myocardial infarction and acute heart failure. Although the contemporary shock stages classification provided a standardized shock severity assessment, individual agents or management strategy has not yet been studied in the context of each shock stage.

Cardiogenic Shock 90

Cardiogenic Shock Myocardial Infarction Heart Failure Outcomes 90

American College of Cardiology

FEBRUARY 6, 2025

The risk of incident heart failure (HF) after a myocardial infarction (MI) is up to six-fold higher than the risk of recurrent MI and the prognosis is worse among those who develop incident HF, regardless of LVEF category.

Myocardial Infarction 65

Myocardial Infarction Heart Failure Article 65

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heart failure (HF).MethodsFrom ConclusionVericiguat combined with the “new quadruple” therapy has a significant therapeutic effect on patients with heart failure caused by MI, DCM or VHD.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

American College of Cardiology

NOVEMBER 7, 2024

Does the development of cardiovascular (CV) events, specifically myocardial infarction (MI) or heart failure (HF), in breast cancer survivors influence their oncologic outcomes?

Cancer 61

Cancer Myocardial Infarction Outcomes Heart Failure 61

Circulation: Heart Failure

NOVEMBER 25, 2024

Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA), has been used to treat patients with heart failure (HF) for more than half a century.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Kidney Disease 40

Journal of the American Heart Association

MARCH 21, 2025

Journal of the American Heart Association, Ahead of Print. BackgroundCarotid intimamedia thickness (CIMT) and carotid distensibility are markers of arterial change; however, little is known of the association with incident heart failure (HF). CIMT but not carotid distensibility was associated with incident myocardial infarction.

Heart Failure 40

Heart Failure Myocardial Infarction Arrhythmia Diabetes 40

European Journal of Heart Failure

JANUARY 25, 2024

Study design and intended outcomes of the HF-REVERT study with CDR132L, a synthetic antisense oligonucleotide inhibitor selectively targeting microRNA-132, in patients with reduced left ventricular ejection fraction (LVEF) after myocardial infarction (MI).

Myocardial Infarction 40

Myocardial Infarction Heart Failure Electrocardiogram Outcomes 40

Circulation

JANUARY 18, 2024

BACKGROUND:Heart failure is associated with a high rate of mortality and morbidity, and ventricular remodeling invariably precedes heart failure. Circulation, Ahead of Print. Ventricular remodeling is fundamentally driven by mechanotransduction that is regulated by both the nervous system and the immune system.

Myocardial Infarction 45

Myocardial Infarction Heart Failure Circulation 45

European Journal of Heart Failure

JANUARY 14, 2025

The International Registry of MitraClip in Acute Mitral Regurgitation following Acute Myocardial Infarction (IREMMI). Methods and results The International Registry of MitraClip in Acute Mitral Regurgitation following Acute Myocardial Infarction (IREMMI) includes 187 patients with severe MR post-MI managed with TEER.

Myocardial Infarction 40

Myocardial Infarction Bicuspid/Mitral Cardiogenic Shock Risk Factors 40

Frontiers in Cardiovascular Medicine

MAY 22, 2024

Takotsubo syndrome (TS), an acute form of heart failure resembling myocardial infarction, manifests with reversible regional wall motion abnormalities (RWMA) of the ventricles. Modelling human diseases serves as a crucial tool to unveil underlying mechanisms and pathophysiology.

Myocardial Infarction 64

Myocardial Infarction Heart Failure Research 64